Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
June 23, 2023 20:45 ET
|
Lexicon Pharmaceuticals, Inc.
First late-stage study will be a Phase 2b dose optimization study, with extension to run in parallel with next-stage Phase 3 studies Feedback obtained from U.S. Food and Drug Administration (FDA) ...
Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions
June 20, 2023 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain INPEFA recently approved for treatment of heart failure THE WOODLANDS, Texas, June 20, 2023 (GLOBE...
UPDATE: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
June 15, 2023 17:00 ET
|
Lexicon Pharmaceuticals, Inc.
INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes INPEFA reduced the risk of total occurrence of...
Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference
June 06, 2023 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, June 06, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies 2023 Global Healthcare Conference, taking...
Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares
June 05, 2023 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, June 05, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the closing of Lexicon’s previously announced public offering and concurrent...
Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement
June 01, 2023 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering...
Lexicon Announces Proposed Public Offering of Common Stock
May 31, 2023 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and...
Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure
May 26, 2023 16:05 ET
|
Lexicon Pharmaceuticals, Inc.
INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes INPEFA reduced the risk of total occurrence...
New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure
May 10, 2023 16:30 ET
|
Lexicon Pharmaceuticals, Inc.
Sotagliflozin reduced the risk of cardiovascular death and heart failure readmissions in patients hospitalized for worsening heart failure events in SOLOIST-WHF study Sotagliflozin NDA for treatment...
Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
May 02, 2023 16:00 ET
|
Lexicon Pharmaceuticals, Inc.
NDA for Sotagliflozin on Track for May 27th, 2023 PDUFA date Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, May 02, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals,...